TY - JOUR
T1 - The Future of Personalized Medicine in Space: From Observations to Countermeasures
AU - Pavez Loriè, Elizabeth
AU - Baatout, Sarah
AU - Choukér, Alexander
AU - Buchheim, Judith-Irina
AU - Baselet, Bjorn
AU - Dello Russo, Cinzia
AU - Wotring, Virginia
AU - Monici, Monica
AU - Morbidelli, Lucia
AU - Gagliardi, Dimitri
AU - Stingl, Julia Caroline
AU - Surdo, Leonardo
AU - Yip, Vincent Lai Ming
PY - 2021
Y1 - 2021
N2 - The aim of personalized medicine is to detach from a “one-size fits all approach” and improve patient health by individualization to achieve the best outcomes in disease prevention, diagnosis and treatment. Technological advances in sequencing, improved knowledge of omics, integration with bioinformatics and new in vitro testing formats, have enabled personalized medicine to become a reality. Individual variation in response to environmental factors can affect susceptibility to disease and response to treatments. Space travel exposes humans to environmental stressors that lead to physiological adaptations, from altered cell behavior to abnormal tissue responses, including immune system impairment. In the context of human space flight research, human health studies have shown a significant inter-individual variability in response to space analogue conditions. A substantial degree of variability has been noticed in response to medications (from both an efficacy and toxicity perspective) as well as in susceptibility to damage from radiation exposure and in physiological changes such as loss of bone mineral density and muscle mass in response to deconditioning. At present, personalized medicine for astronauts is limited. With the advent of longer duration missions beyond low Earth orbit, it is imperative that space agencies adopt a personalized strategy for each astronaut, starting from pre-emptive personalized pre-clinical approaches through to individualized countermeasures to minimize harmful physiological changes and find targeted treatment for disease. Advances in space medicine can also be translated to terrestrial applications, and vice versa. This review places the astronaut at the center of personalized medicine, will appraise existing evidence and future preclinical tools as well as clinical, ethical and legal considerations for future space travel.
AB - The aim of personalized medicine is to detach from a “one-size fits all approach” and improve patient health by individualization to achieve the best outcomes in disease prevention, diagnosis and treatment. Technological advances in sequencing, improved knowledge of omics, integration with bioinformatics and new in vitro testing formats, have enabled personalized medicine to become a reality. Individual variation in response to environmental factors can affect susceptibility to disease and response to treatments. Space travel exposes humans to environmental stressors that lead to physiological adaptations, from altered cell behavior to abnormal tissue responses, including immune system impairment. In the context of human space flight research, human health studies have shown a significant inter-individual variability in response to space analogue conditions. A substantial degree of variability has been noticed in response to medications (from both an efficacy and toxicity perspective) as well as in susceptibility to damage from radiation exposure and in physiological changes such as loss of bone mineral density and muscle mass in response to deconditioning. At present, personalized medicine for astronauts is limited. With the advent of longer duration missions beyond low Earth orbit, it is imperative that space agencies adopt a personalized strategy for each astronaut, starting from pre-emptive personalized pre-clinical approaches through to individualized countermeasures to minimize harmful physiological changes and find targeted treatment for disease. Advances in space medicine can also be translated to terrestrial applications, and vice versa. This review places the astronaut at the center of personalized medicine, will appraise existing evidence and future preclinical tools as well as clinical, ethical and legal considerations for future space travel.
KW - dermatology
KW - future approach
KW - immunology
KW - in vitro modelling
KW - personalized medicine
KW - pharmacology
KW - radiation
KW - space biology
KW - dermatology
KW - future approach
KW - immunology
KW - in vitro modelling
KW - personalized medicine
KW - pharmacology
KW - radiation
KW - space biology
UR - http://hdl.handle.net/10807/193276
UR - https://www.frontiersin.org/articles/10.3389/fbioe.2021.739747/full
U2 - 10.3389/fbioe.2021.739747
DO - 10.3389/fbioe.2021.739747
M3 - Article
SN - 2296-4185
VL - 9
SP - 1
EP - 20
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
ER -